University of Groningen. Diuretic response and renal function in heart failure ter Maaten, Jozine Magdalena

Size: px
Start display at page:

Download "University of Groningen. Diuretic response and renal function in heart failure ter Maaten, Jozine Magdalena"

Transcription

1 University of Groningen Diuretic response and renal function in heart failure ter Maaten, Jozine Magdalena IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2016 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): ter Maaten, J. M. (2016). Diuretic response and renal function in heart failure [Groningen]: Rijksuniversiteit Groningen Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date:

2 2 Diuretic response in acute heart failure pathophysiology, evaluation and therapy Jozine M. ter Maaten, Mattia A.E. Valente, Kevin Damman, Hans L. Hillege, Gerjan Navis, and Adriaan A. Voors Nature Reviews Cardiology 2015;12(3):

3 20 Chapter 2 Abstract The administration of loop diuretics to achieve decongestion is the cornerstone of therapy for acute heart failure. Unfortunately, impaired response to diuretics is common in these patients and associated with adverse outcomes. Diuretic resistance is thought to result from a complex interplay between cardiac and renal dysfunction and specific renal adaptation and escape mechanisms, such as neurohormonal activation and the braking phenomenon. However, our understanding of diuretic response in patients with acute heart failure is still limited and a uniform definition is lacking. Three objective methods to evaluate diuretic response have been introduced, which all suggest that diuretic response should be determined based on the effect of diuretic dose administered. Several strategies have been proposed to overcome diuretic resistance, including combination therapy and ultrafiltration, but prospective studies in patients who are truly unresponsive to diuretics are lacking. An enhanced understanding of diuretic response should ultimately lead to an improved, individualized approach to treating patients with acute heart failure.

4 Diuretic response in acute heart failure 21 Introduction Acute heart failure is one of the leading causes of hospital admission worldwide, and is associated with high morbidity, mortality, and rehospitalization. 1,2 Most of the symptoms associated with acute heart failure are the result of excessive fluid retention, and loop diuretics are the treatment of choice to combat them. Loop diuretics are administered in up to 90% of patients hospitalized for acute heart failure, despite the lack of evidence for outcome benefit. 2,3 Poor response to diuretic therapy (that is, persistent signs and symptoms despite increasing doses of diuretic drug, known as diuretic resistance) frequently occurs in patients during hospitalization for acute heart failure, although the exact frequency is unknown owing to the lack of a standard definition. 4 In two studies from 2014, a poor response to diuretics was more frequently found in patients with diabetes mellitus, reduced glomerular filtration rate (GFR) and high blood urea nitrogen levels, or low systolic blood pressure. 5,6 Importantly, a poor diuretic response was independently associated with impaired symptom relief, a higher risk of in-hospital worsening of heart failure, increased mortality after discharge from hospital, and a threefold higher rate of rehospitalization, compared with patients with a good diuretic response. Moreover, an improved definition and quantification of diuretic response to loop diuretics has been called for by some clinicians. 7 However, the pathophysiology behind diuretic resistance is not completely understood, and thought to result from the complex interplay between cardiac and renal dysfunction, specific renal adaptation, and escape mechanisms, such as the braking phenomenon. 4 In this Review, we describe the pathophysiological background of diuretic resistance, the evaluation and definition of diuretic response, as well as current and future strategies to improve diuretic response in patients with acute heart failure. 2 Pathophysiology The cardiorenal system The heart and kidney function together to regulate circulatory homeostasis via several mechanisms and feedback loops. In healthy individuals, glomerular filtration remains stable despite changes in volume and blood pressure. When triggered by sodium and volume overload, a rise in atrial pressure and release of natriuretic peptides facilitates renal sodium excretion via direct tubular effects and an increase in glomerular filtration rate Concomitant suppression of the renin angiotensin aldosterone system (RAAS) contributes to stable blood pressure via systemic vasodilatation and renal sodium excretion by inhibiting the tubular effects of angiotensin II and aldosterone. 11 Conversely, in a volume depleted state, increased RAAS activity contributes to the maintenance of blood pressure and renal sodium retention. 11 Furthermore, angiotensin II induces renal efferent vasoconstriction,

5 22 Chapter 2 helping to maintain renal filtration pressure and filtration rate despite decreasing arterial pressure. 12 Activation of the sympathetic nervous system has a similar effect as, and is in part stimulated by, the RAAS. 12 Moreover, the interaction of the cardiorenal system affects osmoregulation via effects on water diuresis. Under normal physiological conditions, the release of arginine vasopressin (an antidiuretic hormone) is stimulated by a high plasma osmolarity, which leads to renal water retention and restores normal osmolarity. 13 However, during pronounced water volume disturbances, responses to volume depletion or overload can overcome the osmotic triggers, contributing to restoration of volume status at the expense of osmoregulation. 11 In patients with acute heart failure, a decrease in cardiac function causes reduced cardiac output and arterial underfilling, leading to decreased activation of arterial stretch receptors and resulting in compensatory systemic and intrarenal vasoconstriction. 12 Decreased stretch of the glomerular afferent arteriole stimulates renin release, which leads to angiotensin II production. Angiotensin II release leads to afferent and efferent vasoconstriction, stimulation of sodium retention in the proximal tubule, and release of aldosterone. 14 In turn, aldosterone increases sodium reabsorption in the collecting duct, resulting in extracellular fluid expansion and systemic congestion. 15 In healthy individuals sodium delivery to distal renal tubules by increased vascular volume overcomes the sodium retaining effect of aldosterone (known as an aldosterone escape mechanism). 16 This mechanism is impaired in patients with acute heart failure, in whom reduced renal blood flow forces continued sodium retention in response to aldosterone. 12,16 Heart failure also results in baroreceptor-mediated sympathetic nervous system activation that promotes vasoconstriction and contributes to further RAAS activation and renal sodium and water retention. 17 The release of antidiuretic hormone exacerbates these effects. 18 Furthermore, the protective effect of natriuretic peptides is diminished in patients with acute heart failure due to renal vasoconstriction, reduced sodium delivery, fewer active forms of natriuretic peptides, and downregulation of their receptors. 19,20 In addition, adenosine (released in response to increased renal work load and high sodium concentration in the distal tubule) further reduces renal blood flow, stimulates proximal sodium reabsorption and through tubuloglomerular feedback further decreases GFR via the adenosine A 1 receptor. 21 In contrast to the adenosine A 1 receptor, activation of the adenosine A 2 receptor can increase renin secretion. 21 The combination of these pathways creates a vicious circle that leads to further congestion and worsening heart failure. A major symptom of heart failure is decreased organ perfusion. 1 The kidney can compensate for a drop in renal blood flow by increasing the filtration fraction via angiotensin II mediated efferent vasoconstriction and thereby preserve GFR. 22 The combination of pump failure, neurohormonal activation, and therapies for heart failure, particularly angiotensin-converting-enzyme inhibitors and angiotensin-receptor blockers, can eventually overcome the kidney s capacity to compensate for reduced perfusion. 23,24 Additionally,

6 Diuretic response in acute heart failure 23 increased venous filling and abdominal pressures owing to ascites can increase renal afterload and intrarenal pressure, reduce the transrenal perfusion gradient (and thus renal perfusion pressure), increase renal interstitial pressure (directly opposing filtration pressure), and further contribute to renal insufficiency Mechanisms of diuretic resistance Diuretics are the first-line therapy for volume overload and aim to establish a negative sodium and consequently fluid balance. Poor response to diuretics is an important clinical problem in patients with acute heart failure and its underlying pathophysiological mechanisms are diverse. 2,4 Regulation of renal sodium excretion involves several sequential transport mechanisms in the renal tubule. 28 Diuretics act on specific sodium transport mechanisms, and are classified based on their tubular site of action (Figure 1). Acetazolamide and mannitol act on the proximal tubule, where up to two-thirds of the sodium load is filtered under physiological 2 Figure 1. Diuretic therapy (1) Acetazolamide function in the proximal tubule by blocking carbonic anhydrase an decreasing NaHCO 3 excretion. (2) Mannitol functions in both the proximal tubule and the loop of Henle by increasing H 2 O excretion. (3) Loop diuretics function in thick ascending limb of the loop of Henle by blocking the sodium-chloride-potassium cotransporter and increasing sodium, potassium, and chloride excretion. (4) Thiazide functions in the distal convoluted tubule by blocking the sodium-chloride transporter and increasing sodium chloride excretion. (5) Mineralocorticoid-receptor antagonists function in the collecting duct of the distal tubule and antagonize the aldosterone receptor, hence increasing sodium excretion and potassium retention.

7 24 Chapter 2 conditions. 29,30 Acetazolamide stimulates alkaline diuresis via bicarbonate excretion with sodium and potassium by inhibiting carbonic anhydrase in the proximal tubule. 29 Mannitol is an osmotic diuretic that acts primarily on the loop of Henle and the proximal tubule by increasing the osmotic pressure of glomerular filtrate, thus inhibiting tubular reabsorption. 30 Loop diuretics inhibit solute carrier family 12 member 1 (a sodium chloride potassium cotransporter) in the thick ascending limb of the loop of Henle, leading to decreased sodium and chloride reabsorption from the urine. 28 Thiazide diuretics act on the distal convoluted tubule by blocking the sodium chloride transporter in the distal tubule. 28 Metolazone is a thiazide-like diuretic that exerts its effect in the distal tubule by inhibiting the reabsorption of sodium and chloride ions. 31 Mineralocorticoid-receptor antagonists (MRAs; also known as aldosterone antagonists) act on the collecting duct by competitively antagonizing the mineralocorticoid receptor, thereby reducing sodium reabsorption. 28 Delivery of diuretics to the site of action relies on several mechanisms (Figure 2). First, orally administered diuretics first must be absorbed in the gut to enter the bloodstream. In the presence of gastrointestinal oedema or gut hypoperfusion, absorption of orally administered diuretics is impaired, and might differ substantially between diuretics. 32 For example, Figure 2. Mechanisms of loop diuretic resistance Patients who are resistant to loop diuretics might have reduced absorption of the drug in the intestine, reduced filtration, or increased proximal or distal sodium reabsorption in the kidney, or reduced drug availability in the tubule. Abbreviations: CO, cardiac output; CVP, central venous pressure; GFR, glomerular filtration rate; OAT, organic anion transporter; RAAS, renin-angiotensin-aldosterone system; RBF, renal blood flow; SNS, sympathetic nervous system.

8 Diuretic response in acute heart failure 25 absorption of bumetanide and torsamide is likely to be better than that of furosemide under these conditions. 32,33 Intravenous administration can overcome impaired absorption of orally administered diuretics. In patients with renal insufficiency or heart failure, a higher diuretic dose is required to achieve the same effects and, over time, increasing diuretic doses will become less effective. 4 Second, most loop diuretics (although interestingly bumetanide less so, because it can bind to plasma globulins), thiazide diuretics, metolazone, and acetazolamide are bound to plasma albumin. 34,35 These diuretics act on their molecular target from the luminal side. Consequently, these drugs must be filtered by the glomerulus and actively secreted into the tubular lumen by the proximal tubule s organic anion transporter in order to function. 34 Hypoalbuminaemia, which is common in patients with heart failure, impairs the uptake and secretion of active furosemide and enhances conversion to its inactive form. 36,37 Additionally, albumin lost into the tubule might bind furosemide and prevent it from acting on the sodium chloride potassium co-transporter. 38,39 Coadministration of albumin and furosemide improves diuretic response in patients with cirrhosis, nephrotic syndrome, or chronic kidney disease, but no data are available in individuals with heart failure Third, patients with heart failure and chronic renal dysfunction have elevated levels of circulating organic acids, such as blood urea nitrogen, which competitively inhibit the organic anion transporter and further reduce diuretic availability at the site of action. 43,44 RAAS and sympathetic nervous system activation lead to flow-dependent passive resorption of urea in the distal tubule; a concentration gradient created by increased sodium and water resorption in the proximal tubule results in diminished distal flow and increased reabsorption. 45,46 High circulating blood urea nitrogen levels, therefore, not only contribute directly to diuretic resistance, but also reflect a kidney that is actively working to retain sodium and water. Consequently, in patients with heart failure, impaired absorption, decreased renal blood flow, azotaemia, hypoalbuminaemia, and proteinuria (resulting in reduced levels of active diuretics in the tubular lumen) might affect diuretic effectiveness. At the onset of diuretic treatment, the natriuretic effect results in the intended negative sodium balance. The resulting decrease in extracellular volume triggers a homeostatic response, mediated by activation of the RAAS and sympathetic nervous system, leading to increased sodium retention at tubular sites not targeted by the specific diuretic. 47,48 After several days, this homeostatic response counterbalances the diuretic effect of the drug, balancing sodium excretion and intake, and creating a new steady state with a lower extracellular volume. 47 This braking phenomenon is an appropriate homeostatic response that prevents excessive volume depletion during continued diuretic therapy. However, in patients with pre-existent secondary hyperaldosteronism, such as those with heart failure, this phenomenon can be pronounced, causing rapid and abundant sodium reabsorption and contributing to diuretic resistance. 49 Furthermore, persistent delivery of sodium or diuretics to the distal tubule leads to hypertrophy of the distal tubular cells, 50 which bypasses 2

9 26 Chapter 2 the proximal effect of the loop diuretic and results in enhanced sodium retention. Other noncardiac mechanisms resulting in a diminished response to diuretics, including reduced renal blood flow caused by renal artery stenosis or drug interactions, should also be considered when administering loop diuretics to patients. 28 Evaluating diuretic response No single accepted definition of diuretic resistance has been described. Of the several definitions proposed, the most frequently cited is failure to decongest despite adequate and escalating doses of diuretics. 4 Less clinically applicable definitions that include variables not routinely obtained by clinicians have also been suggested (Box 1). Box 1: Definitions of diuretic resistance Persistent congestion despite adequate and escalating doses of diuretic with >80 mg furosemide per day 107 Amount of sodium excreted as a percentage of filtered load <0.2% 108 Failure to excrete at least 90 mmol of sodium within 72 h of a 160 mg oral furosemide dose given twice daily 109 In our experience, unresponsiveness to diuretic therapy leading to persistent signs and symptoms of congestion is usually considered diuretic resistance. Three objective methods to evaluate diuretic response have been introduced (Box 2). Box 2: Metrics of diuretic response Weight loss per unit of 40 mg furosemide (or equivalent) 5,51 Net fluid loss per milligram of loop diuretic (40 mg of furosemide or equivalent) during hospitalization 6 Natriuretic response to furosemide as the ratio of urinary sodium to urinary furosemide 52 These measures suggest that diuretic response should be determined based on the effect of diuretic dose administered. Some investigators have tried to determine a quantitative measure of diuretic response, combining decongestive effect and diuretic dose. 5 In this study, diuretic response was defined as weight loss from admission to day 4 per 40 mg furosemide (or equivalent). A poor diuretic response independently predicted heart failure rehospitalization (HR 1.58, 95% CI , P <0.001) and mortality (HR 1.73, 95% CI , P <0.001). 5 This metric was investigated in the RELAX-AHF trial, 51 which confirmed these findings (60 day cardiovascular death or heart failure rehospitalization: HR 1.86, 95% CI , P <0.001). Using weight change per unit of furosemide might provide an applicable metric to confirm that a patient is resistant to diuretics. Other investigators have used a similar metric to define diuretic response (termed diuretic efficiency ) defined as net fluid loss per milligram of loop diuretic (40 mg of furosemide or equivalent) during hospitalization for acute heart failure,

10 Diuretic response in acute heart failure 27 dichotomizing above and below the median. 6 Consistent with the results of other investigators, low diuretic efficiency was associated with worse long-term outcomes (HR 1.39, 95% CI , P = 0.007; HR 2.86, 95% CI , P < ). In both studies, poor diuretic response or efficiency was associated with renal impairment and higher blood urea nitrogen levels. 5,6 However, diuretic response is not only a reflection of renal impairment, and poor diuretic response was also associated with more advanced heart failure, diabetes, and atherosclerotic disease. Finally, a ratio of urinary sodium to urinary furosemide measured in spot urine samples was also examined. 52 A poor response (<2 mmol/mg) was associated with impaired clinical outcomes (including death, cardiac transplantation, or rehospitalization owing to heart failure), which were independent of renal function, in patients with acute heart failure (HR 1.62, 95% CI , P = 0.008). 52 Haemoconcentration has also been suggested as a practical and readily applicable strategy to assess diuretic response. 53 The use of urinary sodium and chloride in patients with heart failure to assess decongestion has also been investigated. 54 Decongestion was associated with reduced urinary sodium and chloride excretion per bumetanide dose. Given that urine measurements are not common practice in cardiology, this metric might be less applicable than other metrics, which are easier to obtain and so far have provided similar results to urine measurements. Ultimately, after extensive validation and investigation, the use of such metrics of diuretic response could be used to help to identify patients who might benefit from alternative decongestive therapies and to guide treatment selection. 2 Treatment of patients Several treatment strategies have been proposed to overcome diuretic resistance. An approach to treat patients with acute heart failure who are also diuretic resistant is shown in Figure 3. Overall, we believe in an integrated, patient-tailored approach to improving biological availability of the drugs and counteracting maladaptive responses in patients who are diuretic resistant, which can be attempted using stepped pharmacological therapies, novel drugs, or mechanical fluid removal. Recommendations and scientific evidence for all the treatment options described below are presented in Table 1. Firstly, patient noncompliance to therapy should be ruled out by verifying mediation intake and sodium restriction. 4 Secondly, nonsteroidal inflammatory drugs should be discontinued, because they potentially lead to diuretic resistance by inhibiting prostaglandin G/H synthase 2 (also known as cyclo-oxygenase) and thereby interfere with prostaglandin synthesis, which antagonizes the natriuretic response to loop diuretics. 55 Thirdly, switching to an alternative loop diuretic might be useful to achieve adequate absorption. For example, bumetanide and torasemide both have higher biological absorption than furosemide in patients with chronic heart

11 28 Chapter 2 Figure 3. An approach to treating patients with acute heart failure who are diuretic resistant. If a patient with acute heart failure is diuretic resistant, switch to an alternative loop diuretic. If symptoms persist, intravenously administer the drug before attempting a combination of diuretic therapies. In patients who are still diuretic resistant after these steps, alternative therapies might achieve decongestion. failure. 32,49 In the TORIC study, 56 which included outpatients with heart failure, torasemide treatment was associated with a significant improvement in NYHA class compared with furosemide or other diuretics (improvement of one grade in NYHA class 45.8% versus 37.2%; P <0.001). In a small meta-analysis of 2,025 patients, these findings were confirmed, suggesting a trend toward improvement in NYHA class with torasemide treatment. 57 Adequate increasing doses of loop diuretics have to be prescribed to establish whether a patient truly has diuretic resistance. Finally, efficacy of diuretic therapy can be improved by switching from oral to intravenous administration to circumvent impaired enteral drug uptake in congested patients. 4 The investigators of several small studies have suggested that continuous infusion improves diuresis, renal function, and leads to fewer adverse events compared with bolus injections However, in the Diuretic Optimization Strategies Evaluation 61 no differences in either treatment response or outcome in patients randomized to bolus versus continuous infusion were found, although diuretic doses and the incidence of worsening renal function were higher for patients in the bolus group. However, bolus dosing will not always be carried out as carefully in clinical practice as it was in the study, because this dosing strategy is usually driven by signs and symptoms and not by protocols.

12 Diuretic response in acute heart failure 29 Table 1. Treating diuretic resistant patients with acute heart failure Treatment strategy Author recommendations References Loop diuretic Increasing doses of loop diuretics are considered a Felker et al. 61 first step Switch loop diuretic Switching to bumetanide or torasemide can improve bioavailability of loop diuretic Vargo et al., 32 Brater et al., 33,49 Cosin et al., 56 Bikdeli et al. 57 Intravenous administration Combination therapy Add thiazide Add metalozone Add acetazolamide Intravenous administration of loop diuretic strongly recommended to circumvent impaired enteral uptake Improves sodium excretion by inhibiting distal sodium reabsorption, can be considered when increasing doses of intravenous loop diuretic are insufficient Provides marked diuresis and can produce diuresis despite a low glomerular filtration rate Increases diuresis; caution is recommended in patients with advanced renal failure owing to risk of concentration-dependent adverse effects Dormans et al.,58 Thomson et al., 59 van Meyelet al., 60 Felker et al. 61 Ellison, 28 Kunau et al., 62 Channer et al. 63 Ng et al., 64 Tilstone et al. 65 Brater et al., 66 Khan, 67 Kassamali & Sica, 68 Add mannitol In one study, mannitol improved diuresis Turagam et al., 69 Add MRA at natriuretic doses Dopamine Hypertonic saline Ultrafiltration Associated with increased diuresis; can be considered in addition to combination therapy of loop and thiazide diuretics Does not seem to improve diuretic response in acute heart failure and, therefore, has limited additive value in treating patients who are diuretic resistant Improves diuresis and seems to be a safe alternative strategy in patients who are diuretic resistant Studies on ultrafiltration have not demonstrated consistent improvement; ultrafiltration a last resort when other strategies have failed RALES Investigators, 75 van Vliet et al., 76 Ferreira et al., 77 Sigurd et al.,80 Olesen & Sigurd 81 Elkayam et al., 84 Chen et al., 85 Triposkiadis et al., 86 Giamouzis et al. 87 Paterna et al., 88 Licata et al., 89 Paterna et al., 90 Paterna et al. 91 Bart et al., 93 Costanzo et al., 94 Bart et al. 95 Alternative therapies Tolvaptan Can increase urine output and might have additive Schrier et al., 83 Udelson et al. 99 value Nesiritide Does not increase urine output and is unlikely to have Gottlieb et al. 101 additive value Ularitide Induces natriuresis and diuresis; the TRUE-AHF trial is Valentin et al. 102 ongoing Levosimendan Associated with symptom relief Packer et al. 104 Glucocorticoids Addition of prednisone can result in marked diuresis; Liu et al. 105 an alternative strategy that needs to be studied further Rolofylline Significant predictor of diuretic response and could Valente et al. 5 help to overcome diuretic resistance Serelaxin No significant effect on diuretic response Voors et al., 51 Metra et al. 106 Abbreviation: MRA, mineralocorticoid-receptor antagonist. 2

13 30 Chapter 2 Combined diuretic therapy If escalating intravenous doses of loop diuretics are insufficient, combination therapy with two classes of diuretic drugs might improve diuretic efficacy. The addition of a thiazide diuretic enhances sodium excretion by inhibition of distal sodium reabsorption, 62 and prevent post-diuretic sodium retention after cessation of loop diuretic activity because thiazides have a longer half-life than loop diuretics. 28 Potential adverse effects of combination therapy include hypokalaemia, hyponatraemia, dehydration, worsening renal function and metabolic acidosis; careful monitoring of patients receiving these drugs is, therefore, required. 63 Addition of metozalone to a loop diuretic results in marked diuresis and is especially useful in patients with renal failure, because metozalone can produce diuresis despite a low GFR. 64,65 Given that a large amount of sodium is reabsorbed in the proximal tubule, adding a diuretic that functions in this location might be beneficial to patients. In healthy volunteers, addition of acetazolamide to furosemide showed a minor additive effect on diuresis. 66 In one study, an additional effect of acetazolamide in correcting metabolic acidosis and increased diuresis when used intermittently in combination with furosemide and spironolactone therapy in patients with congestive heart failure was reported. 67 Given that acetazolamide is cleared by the kidney, caution is recommended in patients with advanced renal failure owing to the risk of concentration-dependent adverse effects. 68 Another option for combined therapy is mannitol. Investigators reported effective diuresis in 80.3% of 122 patients with acute heart failure treated with furosemide mannitol infusion, although the study had no control group. 69 To date, studies to evaluate combination therapy in patients with heart failure and who are diuretic resistant are scarce, and evidence remains inconclusive. Two trials (DIURESIS-CHF 70 and CLOROTIC 71 ) to investigate combination therapy in patients with acute heart failure are ongoing and planned, respectively. However, diuretic resistance is not explicitly defined as an inclusion criterion in either study. Adding a natriuretic dose of an MRA to diuretics might also help to overcome diuretic resistance by blocking the mineralocorticoid receptor and thereby prevent excess sodium reabsorption in the collecting duct caused by secondary hyperaldosteronism. 72 MRAs at low doses are guideline-recommended therapy in heart failure and significantly improve survival. 1,73,74 The dose-finding Randomized Aldactone Evaluation Study 75 revealed that higher doses of spironolactone (50 75 mg daily) had natriuretic effects, compared with doses of 12.5 mg or 25 mg daily, which had no natriuretic effect. In two small, single-centre studies of 100 and 21 patients, respectively, high-dose spironolactone was associated with increased diuresis or earlier resolution of symptoms and signs of congestion. 76,77 A common adverse effect of high-dose MRAs is hyperkalaemia; new MRA drugs with a reduced risk of causing electrolyte disturbances are currently being investigated. 78,79 Addition of high-dose MRAs can be considered even in addition to combination therapy with loop and thiazide diuretics. 80,81 In clinical practice, no clear consensus on combination therapy exists and implementation is mostly determined by personal experience. We do not intend to use combination

14 Diuretic response in acute heart failure 31 therapy for outpatients based on the potential complications, which mean that daily monitoring of laboratory values and hydration status is required. Several strategies can be used to prevent or overcome electrolyte disturbances. Hypokalaemia can be avoided by the co-administration of a low-dose potassium-sparing MRA or potassium sparing diuretic. 80,82 Tolvaptan, a vasopressin V 2 receptor blocker, has a potential role in the prevention of hyponatraemia. 83 Overall, combination treatment requires careful follow-up and a tailored approach for each patient. 2 Dopamine Addition of low-dose dopamine (<3 μg/kg/min) to diuretic therapy has been suggested as a method to improve renal blood flow, thereby preserving renal function and improving diuresis. 84 Investigators in the Renal Optimization Strategies Evaluation 85 tested whether addition of low-dose dopamine (2 μg/kg/min), low-dose nesiritide (a synthetic B type natriuretic peptide; μg/kg/min), or placebo, to diuretic therapy enhanced decongestion and preserved renal function in patients with acute heart failure and renal dysfunction. However, neither dopamine nor nesiritide had a significant effect on urine volume (placebo: 8,296 ml; dopamine: 8,524 ml; nesiritide: 8,574 ml) or level of cystatin C (placebo: 0.11 mg/l; dopamine: 0.12 mg/l; nesiritide: 0.07 mg/l), suggesting no added benefit to diuretic therapy. In a subsequent study, investigators in the prematurely discontinued, small-scale Dopamine in Acute Decompensated Heart Failure II trial confirmed these findings, despite promising results from the previous Dopamine in Acute Decompensated Heart Failure I study. 86,87 The results of these studies suggest that dopamine does not improve diuretic response in patients with acute heart failure. Despite the lack of evidence, low-dose dopamine is still often used in clinical practice because this drug is thought to stimulate diuretic response by improving renal function, and might be beneficial in patients for whom other strategies have failed. Hypertonic saline Intravenous hypertonic saline, co-administered with diuretics, has been suggested as a way to improve diuresis, by mobilizing extravascular fluid into the intravascular space resulting in increased cardiac output, renal blood flow, and quick excretion of excess volume. In several small studies of no more than 107 patients, increased diuresis and clinical improvement in patients with acute heart failure was observed with addition of hypertonic saline In the largest study to date (the SMAC HF trial 91), including 1,771 patients, increased diuresis and natriuresis, and reduced rehospitalization rates (18.5% versus 34.2%; P <0.001), were observed in the patients treated with intravenous furosemide and hypertonic saline, compared with those who received furosemide alone. These promising results suggest that hypertonic saline is a safe alternative strategy to improve diuretic response in patients with acute heart failure. However, most experience comes from only a limited number of studies

15 32 Chapter 2 and, therefore, prospective trials in patients who are truly diuretic resistant are needed to establish the role of hypertonic saline. Ultrafiltration Ultrafiltration is an effective method for fluid removal that filters plasma water directly across a semipermeable membrane using a pressure gradient, which yields an ultrafiltrate that is iso-osmotic compared with plasma. 92 In two randomized, controlled trials (RAPID CHF 93 and UNLOAD 94 ) to compare diuretic therapy and ultrafiltration, greater fluid removal was observed in the ultrafiltration groups, although weight loss after 24 h did not differ in RAPID-CHF (P = 0.24), and dyspnoea scores were similar in UNLOAD (P = 0.35). Interestingly, ultrafiltration was associated with significant reductions in rehospitalization for heart failure (18% versus 32%; P = 0.037) and fewer unscheduled hospital visits (21% versus 44%; P = 0.009); unfortunately these results were not adjudicated. In the CARRESS HF study, 95 the investigators examined the use of ultrafiltration in 188 patients with acute heart failure and cardiorenal syndrome. Patients were randomly assigned to receive stepped diuretic therapy or fixed-rate ultrafiltration in a 1:1 ratio (n = 94 per group). Ultrafiltration was inferior to pharmacological therapy, primarily owing to an increase in the creatinine level in the ultrafiltration group (+0.23 ± 0.70 versus 0.04 ± 0.53 mg/dl; P = 0.003), along with more adverse events (72% versus 57%; P = 0.03). However, not all patients in the ultrafiltration group received ultrafiltration therapy, and the fixed rate of fluid removal in the ultrafiltration arm has been questioned. So far, ultrafiltration has not been studied specifically in patients with diuretic resistance. In our opinion, ultrafiltration is a last resort when increasing doses of intravenous loop diuretics, combination therapy or hypertonic saline strategies have failed to overcome diuretic resistance and, even then, only in selected patients who are truly diuretic resistant. Multiple studies on ultrafiltration in heart failure are ongoing, but a phase III outcome trial (AVOID-HF 96 ) was terminated owing to recruitment problems Unfortunately, none of the studies explicitly addresses diuretic resistance in patients. Alternative therapies Various intravenous agents have been investigated in acute heart failure, and although none has shown convincing survival benefits to date, several have mechanisms of action that might be helpful in overcoming diuretic resistance. The vasopressin V 2 receptor blocker, tolvaptan, is effective at increasing sodium concentrations in patients with hyponatraemia, increases urine output in patients with symptomatic heart failure and might, therefore, have additive value in patients who are diuretic resistant. 83,99 Synthetic natriuretic peptides have also been developed and investigated in patients with heart failure. Nesiritide, approved by the FDA in the USA for relief of heart failure symptoms (class IIa, level of evidence C), but not by European regulators owing to a lack of efficacy, 100 did not increase urine output in patients with acute heart failure, and is, therefore, unlikely to have additive value in patients

16 Diuretic response in acute heart failure 33 with diuretic resistance. 101 Ularitide is a synthetic form of the hormone urodilatin, a human endogenous natriuretic peptide expressed in the kidney, and induces natriuresis and diuresis by binding to specific natriuretic peptide receptors. 102 Ularitide might have therapeutic advantages in acute heart failure and specifically in patients who are diuretic resistant, and is being investigated in the ongoing TRUE AHF trial. 103 Levosimendan is a phosphodiesterase inhibitor with vasodilator and positive inotropic properties, which enables rapid and durable symptom relief in acute heart failure and has positive effects on renal function, and which could help to treat symptoms in patients who are diuretic resistant. 104 In a small study of 13 patients with acute heart failure, addition of prednisone in individuals with diuretic resistance led to marked diuresis, significant weight loss (9.39 ± 3.09 kg; P <0.01), and improved renal function (GFR ± ml/min/1.73m 2 ; P <0.01). 105 Further studies are needed to confirm these findings. Finally, treatment with the adenosine A 1 antagonist rolofylline was a significant predictor of diuretic response (t-statistic = 3.091; P = in multivariate models) due to greater weight loss, possibly owing to improved renal perfusion or direct diuretic effects. 5 In some patients with poor diuretic response, inhibition of adenosine A 1 might help to overcome diuretic resistance, although the adverse effect profile of rolofylline, in addition to lack of efficacy, has led to discontinuation of its development. Serelaxin is a human recombinant of the vasodilator relaxin 2, with systemic and renal effects. 106 Although no significant effect of serelaxin on diuretic response has been observed, this drug might have beneficial effects that can prevent organ damage in patients with acute heart failure who are diuretic resistant. 51,106 2 Conclusions Impaired diuretic response is a common problem in patients with acute heart failure and strongly associated with poor in-hospital and post-discharge clinical outcomes. Quantitative measures for diuretic response have been proposed, but need to be validated in other populations of patients with acute heart failure. In addition to establishing the value of diuretic response metrics as prognostic markers, early identification of patients at risk of a poor diuretic response might allow the initiation of therapies to modify their response. Prospective studies using a validated metric of diuretic response to identify patients who are diuretic resistant are a necessary first step towards determining the best strategies for overcoming diuretic resistance, and consequently determining whether such metrics lead to improved outcomes. Such strategies could ultimately result in a better, individualized approach to treating patients with acute decompensated heart failure, for whom no evidencebased therapies currently exist.

17 34 Chapter 2 References 1. McMurray, J. J. et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 33, (2012). 2. Adams, K. F., Jr. et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100, 000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am. Heart J. 149, (2005). 3. Sato, N. et al. Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data. Am. Heart J. 159, 949e1 955e1 (2010). 4. Ellison, D. H. Diuretic therapy and resistance in congestive heart failure. Cardiology 96, (2001). 5. Valente, M. A. et al. Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur. Heart J. 35, (2014). 6. Testani, J. M. et al. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ. Heart Fail. 7, (2014). 7. Braunwald, E. Responsiveness to loop diuretics in heart failure. Eur. Heart J. 35, (2014). 8. Cadnapaphornchai, M. A., Gurevich, A. K., Weinberger, H. D. & Schrier, R. W. Pathophysiology of sodium and water retention in heart failure. Cardiology 96, (2001). 9. Levin, E. R., Gardner, D. G. & Samson, W. K. Natriuretic peptides. N. Engl. J. Med. 339, (1998). 10. Harris, P. J., Thomas, D. & Morgan, T. O. Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption. Nature 326, (1987). 11. Guyton, A. & Hall, J. in Medical physiology (Elsevier Saunders, 2006). 12. Schrier, R. W. & Abraham, W. T. Hormones and hemodynamics in heart failure. N. Engl. J. Med. 341, (1999). 13. Baylis, P. H. Osmoregulation and control of vasopressin secretion in healthy humans. Am. J. Physiol. 253, R (1987). 14. Unger, T. & Li, J. The role of the renin angiotensin aldosterone system in heart failure. J. Renin Angiotensin Aldosterone Syst. 5 (Suppl. 1), S7 S10 (2004). 15. Weber, K. T. Aldosterone in congestive heart failure. N. Engl. J. Med. 345, (2001). 16. Schrier, R. W. Aldosterone escape vs breakthrough. Nat. Rev. Nephrol. 6, 61 (2010). 17. Levine, T. B., Francis, G. S., Goldsmith, S. R., Simon, A. B. & Cohn, J. N. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am. J. Cardiol. 49, (1982). 18. Schrier, R. W., Berl, T. & Anderson, R. J. Osmotic and nonosmotic control of vasopressin release. Am. J. Physiol. 236, F321 F332 (1979). 19. Charloux, A., Piquard, F., Doutreleau, S., Brandenberger, G. & Geny, B. Mechanisms of renal hyporesponsiveness to ANP in heart failure. Eur. J. Clin. Invest. 33, (2003). 20. Liang, F. et al. Evidence for functional heterogeneity of circulating B type natriuretic peptide. J. Am. Coll. Cardiol. 49, (2007). 21. Vallon, V., Miracle, C. & Thomson, S. Adenosine and kidney function: potential implications in patients with heart failure. Eur. J. Heart Fail. 10, (2008). 22. Damman, K., Voors, A. A., Navis, G., van Veldhuisen, D. J. & Hillege, H. L. The cardiorenal syndrome in heart failure. Prog. Cardiovasc. Dis. 54, (2011).

18 Diuretic response in acute heart failure Smilde, T. D. et al. Differential associations between renal function and modifiable risk factors in patients with chronic heart failure. Clin. Res. Cardiol. 98, (2009). 24. Hillege, H. L. et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102, (2000). 25. Damman, K. et al. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur. J. Heart Fail. 9, (2007). 26. Damman, K. et al. Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Eur. J. Heart Fail. 12, (2010). 27. Mullens, W. et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J. Am. Coll. Cardiol. 53, (2009). 28. Ellison, D. H. The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann. Intern. Med. 114, (1991). 29. Maren, T. H. Use of inhibitors in physiological studies of carbonic anhydrase. Am. J. Physiol. 232, F291 F297 (1977). 30. Warren, S. E. & Blantz, R. C. Mannitol. Arch. Intern. Med. 141, (1981). 31. Steinmuller, S. T. & Puschett, J. B. Effects of metolazone in man: comparison with chlorothiazide. Kidney Int. 1, (1972). 32. Vargo, D. L. et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin. Pharmacol. Ther. 57, (1995). 33. Brater, D. C., Day, B., Burdette, A. & Anderson, S. Bumetanide and furosemide in heart failure. Kidney Int. 26, (1984). 34. Uwai, Y., Saito, H., Hashimoto, Y. & Inui, K. I. Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter roat1. J. Pharmacol. Exp. Ther. 295, (2000). 35. Kim, E. J. & Lee, M. G. Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. Biopharm. Drug Dispos. 22, (2001). 36. Jackson, C. E. et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 374, (2009). 37. Hesse, B., Parving, H. H., Lund-Jacobsen, H. & Noer, I. Transcapillary escape rate of albumin and right atrial pressure in chronic congestive heart failure before and after treatment. Circ. Res. 39, (1976). 38. Bowman, R. H. Renal secretion of [35 S]furosemide and depression by albumin binding. Am. J. Physiol. 229, (1975). 39. Pichette, V., Geadah, D. & du Souich, P. The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit. Br. J. Pharmacol. 119, (1996). 40. Gentilini, P. et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J. Hepatol. 30, (1999). 41. Ghafari, A. et al. Co-administration of albumin-furosemide in patients with the nephrotic syndrome. Saudi J. Kidney Dis. Transpl. 22, (2011). 42. Phakdeekitcharoen, B. & Boonyawat, K. The added-up albumin enhances the diuretic effect of furosemide in patients with hypoalbuminemic chronic kidney disease: a randomized controlled study. BMC Nephrol. 13, 92 (2012). 43. Sweet, D. H., Bush, K. T. & Nigam, S. K. The organic anion transporter family: from physiology to ontogeny and the clinic. Am. J. Physiol. Renal Physiol. 281, F197 F205 (2001). 2

19 36 Chapter Krick, W., Wolff, N. A. & Burckhardt, G. Voltage-driven p aminohippurate, chloride, and urate transport in porcine renal brush-border membrane vesicles. Pflugers Arch. 441, (2000). 45. Kazory, A. Emergence of blood urea nitrogen as a biomarker of neurohormonal activation in heart failure. Am. J. Cardiol. 106, (2010). 46. Schrier, R. W. Blood urea nitrogen and serum creatinine: not married in heart failure. Circ. Heart Fail. 1, 2 5 (2008). 47. Wilcox, C. S. et al. Response of the kidney to furosemide. I. Effects of salt intake and renal compensation. J. Lab. Clin. Med. 102, (1983). 48. Loon, N. R., Wilcox, C. S. & Unwin, R. J. Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int. 36, (1989). 49. Brater, D. C. Diuretic therapy. N. Engl. J. Med. 339, (1998). 50. Kaissling, B., Bachmann, S. & Kriz, W. Structural adaptation of the distal convoluted tubule to prolonged furosemide treatment. Am. J. Physiol. 248, F374 F381 (1985). 51. Voors, A. A. et al. Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome-an analysis from RELAX-AHF. Eur. J. Heart Fail. 16, (2014). 52. Singh, D. et al. Insufficient natriuretic response to continuous intravenous furosemide is associated with poor long-term outcomes in acute decompensated heart failure. J. Card. Fail. 20, (2014). 53. Vaduganathan, M. et al. Hemoconcentration-Guided Diuresis in Heart Failure. Am. J. Med. 127, (2014). 54. Verbrugge, F. H. et al. Urinary composition during decongestive treatment in heart failure with reduced ejection fraction. Circ. Heart Fail. 7, (2014). 55. Johnston, G. D. et al. Factors modifying the early nondiuretic vascular effects of furosemide in man. The possible role of renal prostaglandins. Circ. Res. 53, (1983). 56. Cosin, J., Diez, J. & TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur. J. Heart Fail. 4, (2002). 57. Bikdeli, B. et al. Dominance of furosemide for loop diuretic therapy in heart failure: time to revisit the alternatives? J. Am. Coll. Cardiol. 61, (2013). 58. Dormans, T. P. et al. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J. Am. Coll. Cardiol. 28, (1996). 59. Thomson, M. R. et al. Continuous versus intermittent infusion of furosemide in acute decompensated heart failure. J. Card. Fail. 16, (2010). 60. van Meyel, J. J. et al. Continuous infusion of furosemide in the treatment of patients with congestive heart failure and diuretic resistance. J. Intern. Med. 235, (1994). 61. Felker, G. M. et al. Diuretic strategies in patients with acute decompensated heart failure. N. Engl. J. Med. 364, (2011). 62. Kunau, R. T., Jr, Weller, D. R. & Webb, H. L. Clarification of the site of action of chlorothiazide in the rat nephron. J. Clin. Invest. 56, (1975). 63. Channer, K. S., McLean, K. A., Lawson-Matthew, P. & Richardson, M. Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br. Heart J. 71, (1994). 64. Ng, T. M. et al. Comparison of bumetanide- and metolazone-based diuretic regimens to furosemide in acute heart failure. J. Cardiovasc. Pharmacol. Ther. 18, (2013). 65. Tilstone, W. J., Dargie, H., Dargie, E. N., Morgan, H. G. & Kennedy, A. C. Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure. Clin. Pharmacol. Ther. 16, (1974).

Citation for published version (APA): Valente, M. (2015). Diuretic response and cardiorenal interaction in heart failure [S.l.]: [S.n.

Citation for published version (APA): Valente, M. (2015). Diuretic response and cardiorenal interaction in heart failure [S.l.]: [S.n. University of Groningen Diuretic response and cardiorenal interaction in heart failure Valente, Mattia IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to

More information

The Art and Science of Diuretic therapy

The Art and Science of Diuretic therapy The Art and Science of Diuretic therapy Dr. Fayez EL Shaer Associate Professour of cardiology Consultant cardiologist MD, MSc, PhD, CBNC, NBE FESC, ACCP, FASNC,HFA KKUH, KFCC Heart failure: fluid overload

More information

Pivotal Role of Renal Function in Acute Heart failure

Pivotal Role of Renal Function in Acute Heart failure Pivotal Role of Renal Function in Acute Heart failure Doron Aronson MD, FESC Department of Cardiology RAMBAM Health Care Campus Haifa, Israel Classification and definitions of cardiorenal syndromes CRS

More information

Journal Watch. January. REVIEW: Diuretic Resistance in heart failure HEART FAILURE AND TRANSPLANTATION

Journal Watch. January. REVIEW: Diuretic Resistance in heart failure HEART FAILURE AND TRANSPLANTATION Journal Watch January 2018 Lavanya Bellumkonda, MD, PhD Yale University School of Medicine New Haven, Connecticut, USA lavanya.bellumkonda@yale.edu Josephine Chou, MD Yale University School of Medicine

More information

University of Groningen. Diuretic response and renal function in heart failure ter Maaten, Jozine Magdalena

University of Groningen. Diuretic response and renal function in heart failure ter Maaten, Jozine Magdalena University of Groningen Diuretic response and renal function in heart failure ter Maaten, Jozine Magdalena IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish

More information

Overcoming the Cardiorenal Syndrome

Overcoming the Cardiorenal Syndrome Overcoming the Cardiorenal Syndrome October 29, 2016 Randall C Starling MD MPH FACC FESC FHFSA FHFA Professor of Medicine Heart & Vascular Institute Cleveland Clinic Lerner College of Medicine Cleveland

More information

The Cardiorenal Syndrome in Heart Failure

The Cardiorenal Syndrome in Heart Failure The Cardiorenal Syndrome in Heart Failure Van N Selby, MD Assistant Professor of Medicine Advanced Heart Failure Program, UCSF October 9, 2015 Disclosures None 1 Cardiorenal Syndrome (CRS) A pathophysiologic

More information

Hyponatremia in Heart Failure: why it is important and what should we do about it?

Hyponatremia in Heart Failure: why it is important and what should we do about it? Objectives Hyponatremia in Heart Failure: why it is important and what should we do about it? Pathophysiology of sodium and water retention in heart failure Hyponatremia in heart failure (mechanism and

More information

Medical Management of Acutely Decompensated Heart Failure. William T. Abraham, MD Director, Division of Cardiovascular Medicine

Medical Management of Acutely Decompensated Heart Failure. William T. Abraham, MD Director, Division of Cardiovascular Medicine Medical Management of Acutely Decompensated Heart Failure William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Goals of Acute Heart Failure Therapy Alleviate

More information

Heart Failure and Renal Disease Cardiorenal Syndrome

Heart Failure and Renal Disease Cardiorenal Syndrome Advanced Heart Failure: Clinical Challenges Heart Failure and Renal Disease Cardiorenal Syndrome 17 th Apr 2015 Ju-Hee Lee, M.D Cardiovascular Center, Chungbuk National University Hospital Chungbuk National

More information

Heart Failure and Renal Failure. Gerasimos Filippatos, MD, FESC, FHFA President HFA

Heart Failure and Renal Failure. Gerasimos Filippatos, MD, FESC, FHFA President HFA Heart Failure and Renal Failure Gerasimos Filippatos, MD, FESC, FHFA President HFA Definition Epidemiology Pathophysiology Management (?) Recommendations for NHLBI in cardiorenal interactions related to

More information

Renal Quiz - June 22, 21001

Renal Quiz - June 22, 21001 Renal Quiz - June 22, 21001 1. The molecular weight of calcium is 40 and chloride is 36. How many milligrams of CaCl 2 is required to give 2 meq of calcium? a) 40 b) 72 c) 112 d) 224 2. The extracellular

More information

BIPN100 F15 Human Physiology (Kristan) Lecture 18: Endocrine control of renal function. p. 1

BIPN100 F15 Human Physiology (Kristan) Lecture 18: Endocrine control of renal function. p. 1 BIPN100 F15 Human Physiology (Kristan) Lecture 18: Endocrine control of renal function. p. 1 Terms you should understand by the end of this section: diuresis, antidiuresis, osmoreceptors, atrial stretch

More information

THE KIDNEY IN HYPOTENSIVE STATES. Benita S. Padilla, M.D.

THE KIDNEY IN HYPOTENSIVE STATES. Benita S. Padilla, M.D. THE KIDNEY IN HYPOTENSIVE STATES Benita S. Padilla, M.D. Objectives To discuss what happens when the kidney encounters low perfusion To discuss new developments and clinical application points in two scenarios

More information

Cardiorenal Syndrome: What the Clinician Needs to Know. William T. Abraham, MD Director, Division of Cardiovascular Medicine

Cardiorenal Syndrome: What the Clinician Needs to Know. William T. Abraham, MD Director, Division of Cardiovascular Medicine Cardiorenal Syndrome: What the Clinician Needs to Know William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Renal Hemodynamics in Heart Failure Glomerular

More information

Chapter 21. Diuretic Agents. Mosby items and derived items 2008, 2002 by Mosby, Inc., an affiliate of Elsevier Inc.

Chapter 21. Diuretic Agents. Mosby items and derived items 2008, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 21 Diuretic Agents Renal Structure and Function Kidneys at level of umbilicus Each weighs 160 to 175 g and is 10 to 12 cm long Most blood flow per gram of weight in body 22% of cardiac output (CO)

More information

014 Chapter 14 Created: 9:25:14 PM CST

014 Chapter 14 Created: 9:25:14 PM CST 014 Chapter 14 Created: 9:25:14 PM CST Student: 1. Functions of the kidneys include A. the regulation of body salt and water balance. B. hydrogen ion homeostasis. C. the regulation of blood glucose concentration.

More information

Hyponatremia as a Cardiovascular Biomarker

Hyponatremia as a Cardiovascular Biomarker Hyponatremia as a Cardiovascular Biomarker Uri Elkayam, MD Professor of Medicine University of Southern California Keck School of Medicine elkayam@usc.edu Disclosure Research grant from Otsuka for the

More information

Cardiorenal Syndrome

Cardiorenal Syndrome SOCIEDAD ARGENTINA DE CARDIOLOGIA Cardiorenal Syndrome Joint session ESC-SAC ESC Congress 2012, Munich César A. Belziti Hospital Italiano de Buenos Aires I have no conflicts of interest to declare Cardiorenal

More information

Cardio-Renal Syndrome in Acute Heart Failure:

Cardio-Renal Syndrome in Acute Heart Failure: Cardio-Renal Syndrome in Acute Heart Failure: Target for Therapy Marvin A. Konstam, M.D. Research support and/or consulting relevant to this lecture: Merck, Otsuka, Johnson & Johnson; Amgen; Cardiokine

More information

Monitoring of Renal Function in Heart Failure

Monitoring of Renal Function in Heart Failure Monitoring of Renal Function in Heart Failure Adriaan A. Voors, cardiologist The Netherlands Disclosures AAV received consultancy fees and/or research grants from: Alere, Bayer, Cardio3Biosciences, Celladon,

More information

Cardiorenal syndrome. Sofie Gevaert. Ghent University Hospital, Belgium

Cardiorenal syndrome. Sofie Gevaert. Ghent University Hospital, Belgium Cardiorenal syndrome Sofie Gevaert Ghent University Hospital, Belgium Disclosures Consultancy Astra Zeneca Boegringer MSD Novartis 68 y old man, ADHF ICMP, ejection fraction 35 %: progressive dyspnea,

More information

BIPN100 F15 Human Physiology (Kristan) Problem Set #8 Solutions p. 1

BIPN100 F15 Human Physiology (Kristan) Problem Set #8 Solutions p. 1 BIPN100 F15 Human Physiology (Kristan) Problem Set #8 Solutions p. 1 1. a. Proximal tubule. b. Proximal tubule. c. Glomerular endothelial fenestrae, filtration slits between podocytes of Bowman's capsule.

More information

Physio 12 -Summer 02 - Renal Physiology - Page 1

Physio 12 -Summer 02 - Renal Physiology - Page 1 Physiology 12 Kidney and Fluid regulation Guyton Ch 20, 21,22,23 Roles of the Kidney Regulation of body fluid osmolarity and electrolytes Regulation of acid-base balance (ph) Excretion of natural wastes

More information

Regulation of Body Fluids: Na + and Water Linda Costanzo, Ph.D.

Regulation of Body Fluids: Na + and Water Linda Costanzo, Ph.D. Regulation of Body Fluids: Na + and Water Linda Costanzo, Ph.D. OBJECTIVES: After studying this lecture, the student should understand: 1. Why body sodium content determines ECF volume and the relationships

More information

Therapeutics of Diuretics

Therapeutics of Diuretics (Last Updated: 08/22/2018) Created by: Socco, Samantha Therapeutics of Diuretics Thambi, M. (2017). The Clinical Use of Diuretics. Lecture presented at PHAR 503 Lecture in UIC College of Pharmacy, Chicago.

More information

State-of-the-Art: Treatment of Renal Dysfunction in Heart Failure. W. H. Wilson Tang, MD Cleveland Clinic, U.S.A.

State-of-the-Art: Treatment of Renal Dysfunction in Heart Failure. W. H. Wilson Tang, MD Cleveland Clinic, U.S.A. State-of-the-Art: Treatment of Renal Dysfunction in Heart Failure W. H. Wilson Tang, MD Cleveland Clinic, U.S.A. Heart Failure Exacerbates Renal Insufficiency ADHERE Registry: Prevalence of CKD by egfr

More information

Renal Regulation of Sodium and Volume. Dr. Dave Johnson Associate Professor Dept. Physiology UNECOM

Renal Regulation of Sodium and Volume. Dr. Dave Johnson Associate Professor Dept. Physiology UNECOM Renal Regulation of Sodium and Volume Dr. Dave Johnson Associate Professor Dept. Physiology UNECOM Maintaining Volume Plasma water and sodium (Na + ) are regulated independently - you are already familiar

More information

Glomerular Capillary Blood Pressure

Glomerular Capillary Blood Pressure Glomerular Capillary Blood Pressure Fluid pressure exerted by blood within glomerular capillaries Depends on Contraction of the heart Resistance to blood flow offered by afferent and efferent arterioles

More information

RENAL PHYSIOLOGY. Physiology Unit 4

RENAL PHYSIOLOGY. Physiology Unit 4 RENAL PHYSIOLOGY Physiology Unit 4 Renal Functions Primary Function is to regulate the chemistry of plasma through urine formation Additional Functions Regulate concentration of waste products Regulate

More information

Diuretics having the quality of exciting excessive excretion of urine. OED. Inhibitors of Sodium Reabsorption Saluretics not Aquaretics

Diuretics having the quality of exciting excessive excretion of urine. OED. Inhibitors of Sodium Reabsorption Saluretics not Aquaretics Diuretics having the quality of exciting excessive excretion of urine. OED Inhibitors of Sodium Reabsorption Saluretics not Aquaretics 1 Sodium Absorption Na Entry into the Cell down an electrochemical

More information

Renal Pharmacology. Diuretics: Carbonic Anhydrase Inhibitors Thiazides Loop Diuretics Potassium-sparing Diuretics BIMM118

Renal Pharmacology. Diuretics: Carbonic Anhydrase Inhibitors Thiazides Loop Diuretics Potassium-sparing Diuretics BIMM118 Diuretics: Carbonic Anhydrase Inhibitors Thiazides Loop Diuretics Potassium-sparing Diuretics Renal Pharmacology Kidneys: Represent 0.5% of total body weight, but receive ~25% of the total arterial blood

More information

Diuretic Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Diuretic Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Diuretic Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Potassium-sparing diuretics The Ion transport pathways across the luminal and basolateral

More information

Questions? Homework due in lab 6. PreLab #6 HW 15 & 16 (follow directions, 6 points!)

Questions? Homework due in lab 6. PreLab #6 HW 15 & 16 (follow directions, 6 points!) Questions? Homework due in lab 6 PreLab #6 HW 15 & 16 (follow directions, 6 points!) Part 3 Variations in Urine Formation Composition varies Fluid volume Solute concentration Variations in Urine Formation

More information

Vertebrates possess kidneys: internal organs which are vital to ion and water balance and excretion.

Vertebrates possess kidneys: internal organs which are vital to ion and water balance and excretion. The Kidney Vertebrates possess kidneys: internal organs which are vital to ion and water balance and excretion. The kidney has 6 roles in the maintenance of homeostasis. 6 Main Functions 1. Ion Balance

More information

Pharmacology I [PHL 313] Diuretics. Dr. Mohammad Nazam Ansari

Pharmacology I [PHL 313] Diuretics. Dr. Mohammad Nazam Ansari Pharmacology I [PHL 313] Diuretics Dr. Mohammad Nazam Ansari Renal Pharmacology Kidneys: Each adult kidney weighs 125-170g in males and 115-155g in females, represent 0.5% of total body weight, but receive

More information

Objectives 6/14/2016. Cardiorenal Syndrome: Critical Link Between Heart and Kidney

Objectives 6/14/2016. Cardiorenal Syndrome: Critical Link Between Heart and Kidney Cardiorenal Syndrome: Critical Link Between Heart and Kidney Chris M. Bell, ACNP Cardiology Associates of North Mississippi Objectives Review the 5 Subtypes of the Cardiorenal Syndrome (CRS) Discuss the

More information

ROSE-AHF and Beyond. Gerasimos Filippatos, FESC, FHFA President Heart Failure Association

ROSE-AHF and Beyond. Gerasimos Filippatos, FESC, FHFA President Heart Failure Association ROSE-AHF and Beyond Gerasimos Filippatos, FESC, FHFA President Heart Failure Association From: Braunwald s Heart Disease. 9th ed. Philadelphia, Elsevier, 2011 Determinants and forms of worsening renal

More information

DIURETICS-4 Dr. Shariq Syed

DIURETICS-4 Dr. Shariq Syed DIURETICS-4 Dr. Shariq Syed AIKTC - Knowledge Resources & Relay Center 1 Pop Quiz!! Loop diuretics act on which transporter PKCC NKCC2 AIKTCC I Don t know AIKTC - Knowledge Resources & Relay Center 2 Pop

More information

KD02 [Mar96] [Feb12] Which has the greatest renal clearance? A. PAH B. Glucose C. Urea D. Water E. Inulin

KD02 [Mar96] [Feb12] Which has the greatest renal clearance? A. PAH B. Glucose C. Urea D. Water E. Inulin Renal Physiology MCQ KD01 [Mar96] [Apr01] Renal blood flow is dependent on: A. Juxtaglomerular apparatus B. [Na+] at macula densa C. Afferent vasodilatation D. Arterial pressure (poorly worded/recalled

More information

Management of Acute Heart Failure

Management of Acute Heart Failure Management of Acute Heart Failure Uri Elkayam, MD Professor of Medicine University of Southern California School of Medicine Los Angeles, California elkayam@usc.edu ADHF Treatments Goals.2 Improve symptoms.

More information

DIURETICS. Assoc. Prof. Bilgen Başgut

DIURETICS. Assoc. Prof. Bilgen Başgut DIURETICS Assoc. Prof. Bilgen Başgut Classification of Diuretics The best way to classify diuretics is to look for their Site of action in the nephron A. Diuretics that inhibit transport in the Proximal

More information

The principal functions of the kidneys

The principal functions of the kidneys Renal physiology The principal functions of the kidneys Formation and excretion of urine Excretion of waste products, drugs, and toxins Regulation of body water and mineral content of the body Maintenance

More information

Antialdosterone treatment in heart failure

Antialdosterone treatment in heart failure Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition

More information

Chapter 19 The Urinary System Fluid and Electrolyte Balance

Chapter 19 The Urinary System Fluid and Electrolyte Balance Chapter 19 The Urinary System Fluid and Electrolyte Balance Chapter Outline The Concept of Balance Water Balance Sodium Balance Potassium Balance Calcium Balance Interactions between Fluid and Electrolyte

More information

Defining and Managing the Cardiorenal Syndrome in Acute Decompensated Heart Failure. Barry M. Massie Professor of Medicine UCSF

Defining and Managing the Cardiorenal Syndrome in Acute Decompensated Heart Failure. Barry M. Massie Professor of Medicine UCSF Defining and Managing the Cardiorenal Syndrome in Acute Decompensated Heart Failure Barry M. Massie Professor of Medicine UCSF DISCLOSURES Consulting fees: Merck-Novacardia Novartis Bristol Myers Squibb

More information

Low Efficacy Diuretics. Potassium sparing diuretics. Carbonic anhydrase inhibitors. Osmotic diuretics. Miscellaneous

Low Efficacy Diuretics. Potassium sparing diuretics. Carbonic anhydrase inhibitors. Osmotic diuretics. Miscellaneous University of Al Qadisiyah College of Pharmacy Dr. Bassim I Mohammad, MBChB, MSc, Ph.D Low Efficacy Diuretics 1. Potassium sparing diuretics 2. Carbonic anhydrase inhibitors 3. Osmotic diuretics 4. Miscellaneous

More information

** TMP mean page 340 in 12 th edition. Questions 1 and 2 Use the following clinical laboratory test results for questions 1 and 2:

** TMP mean page 340 in 12 th edition. Questions 1 and 2 Use the following clinical laboratory test results for questions 1 and 2: QUESTION Questions 1 and 2 Use the following clinical laboratory test results for questions 1 and 2: Urine flow rate = 1 ml/min Urine inulin concentration = 100 mg/ml Plasma inulin concentration = 2 mg/ml

More information

Renal-Related Questions

Renal-Related Questions Renal-Related Questions 1) List the major segments of the nephron and for each segment describe in a single sentence what happens to sodium there. (10 points). 2) a) Describe the handling by the nephron

More information

One Minute Movies: Molecular Action at the Nephron Joy Killough / Westwood High School / Austin,TX

One Minute Movies: Molecular Action at the Nephron Joy Killough / Westwood High School / Austin,TX One Minute Movies: Molecular Action at the Nephron Joy Killough / Westwood High School / Austin,TX To prepare your nephron model: ( A nephron is a tubule and the glomerulus. There are about a million of

More information

Osmotic Regulation and the Urinary System. Chapter 50

Osmotic Regulation and the Urinary System. Chapter 50 Osmotic Regulation and the Urinary System Chapter 50 Challenge Questions Indicate the areas of the nephron that the following hormones target, and describe when and how the hormones elicit their actions.

More information

Cardiorenal Syndrome Prof. Dr. Bülent ALTUN Hacettepe University Faculty of Medicine Department of Internal Medicine Division of Nephrology

Cardiorenal Syndrome Prof. Dr. Bülent ALTUN Hacettepe University Faculty of Medicine Department of Internal Medicine Division of Nephrology Cardiorenal Syndrome Prof. Dr. Bülent ALTUN Hacettepe University Faculty of Medicine Department of Internal Medicine Division of Nephrology Heart and Kidney The kidney yin dominates water, The heart yang

More information

Answers and Explanations

Answers and Explanations Answers and Explanations 1. The answer is D [V B 4 b]. Distal K + secretion is decreased by factors that decrease the driving force for passive diffusion of K + across the luminal membrane. Because spironolactone

More information

Renal Physiology Part II. Bio 219 Napa Valley College Dr. Adam Ross

Renal Physiology Part II. Bio 219 Napa Valley College Dr. Adam Ross Renal Physiology Part II Bio 219 Napa Valley College Dr. Adam Ross Fluid and Electrolyte balance As we know from our previous studies: Water and ions need to be balanced in order to maintain proper homeostatic

More information

BIOL 2402 Fluid/Electrolyte Regulation

BIOL 2402 Fluid/Electrolyte Regulation Dr. Chris Doumen Collin County Community College BIOL 2402 Fluid/Electrolyte Regulation 1 Body Water Content On average, we are 50-60 % water For a 70 kg male = 40 liters water This water is divided into

More information

Urinary System Organization. Urinary System Organization. The Kidneys. The Components of the Urinary System

Urinary System Organization. Urinary System Organization. The Kidneys. The Components of the Urinary System Urinary System Organization The Golden Rule: The Job of The Urinary System is to Maintain the Composition and Volume of ECF remember this & all else will fall in place! Functions of the Urinary System

More information

Biomarkers, the Kidney and the Heart: Acute Kidney Injury

Biomarkers, the Kidney and the Heart: Acute Kidney Injury Biomarkers, the Kidney and the Heart: Acute Kidney Injury 12th Annual Conference on Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices San Diego May 13, 2016 Ravindra

More information

Biomarkers for optimal management of heart failure. Cardiorenal syndrome. Veli-Pekka Harjola Helsinki University Central Hospital Helsinki, Finland

Biomarkers for optimal management of heart failure. Cardiorenal syndrome. Veli-Pekka Harjola Helsinki University Central Hospital Helsinki, Finland Biomarkers for optimal management of heart failure Cardiorenal syndrome Veli-Pekka Harjola Helsinki University Central Hospital Helsinki, Finland Presenter Disclosure Information V-P Harjola The following

More information

Regulation of fluid and electrolytes balance

Regulation of fluid and electrolytes balance Regulation of fluid and electrolytes balance Three Compartment Fluid Compartments Intracellular = Cytoplasmic (inside cells) Extracellular compartment is subdivided into Interstitial = Intercellular +

More information

DIAGNOSIS AND MANAGEMENT OF DIURETIC RESISTANCE. Jules B. Puschett, M.D.

DIAGNOSIS AND MANAGEMENT OF DIURETIC RESISTANCE. Jules B. Puschett, M.D. DIAGNOSIS AND MANAGEMENT OF DIURETIC RESISTANCE Jules B. Puschett, M.D. Diuretic Resistance A clinical circumstance in which patients do not respond to a combination of salt restriction and even large

More information

Nephron Structure inside Kidney:

Nephron Structure inside Kidney: In-Depth on Kidney Nephron Structure inside Kidney: - Each nephron has two capillary regions in close proximity to the nephron tubule, the first capillary bed for fluid exchange is called the glomerulus,

More information

Case Presentation. This presentation is the intellectual property of the author. Contact them for permission to reprint and/or distribute.

Case Presentation. This presentation is the intellectual property of the author. Contact them for permission to reprint and/or distribute. Worsening Renal Function in Heart Failure Patients Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center

More information

Excretion Chapter 29. The Mammalian Excretory System consists of. The Kidney. The Nephron: the basic unit of the kidney.

Excretion Chapter 29. The Mammalian Excretory System consists of. The Kidney. The Nephron: the basic unit of the kidney. Excretion Chapter 29 The Mammalian Excretory System consists of The Kidney 1. Vertebrate kidneys perform A. Ion balance B. Osmotic balance C. Blood pressure D. ph balance E. Excretion F. Hormone production

More information

I. Metabolic Wastes Metabolic Waste:

I. Metabolic Wastes Metabolic Waste: I. Metabolic Wastes Metabolic Waste: a) Carbon Dioxide: by-product of cellular respiration. b) Water: by-product of cellular respiration & dehydration synthesis reactions. c) Inorganic Salts: by-product

More information

Outline Urinary System. Urinary System and Excretion. Urine. Urinary System. I. Function II. Organs of the urinary system

Outline Urinary System. Urinary System and Excretion. Urine. Urinary System. I. Function II. Organs of the urinary system Outline Urinary System Urinary System and Excretion Bio105 Chapter 16 Renal will be on the Final only. I. Function II. Organs of the urinary system A. Kidneys 1. Function 2. Structure III. Disorders of

More information

University of Groningen. Acute kidney injury after cardiac surgery Loef, Berthus Gerard

University of Groningen. Acute kidney injury after cardiac surgery Loef, Berthus Gerard University of Groningen Acute kidney injury after cardiac surgery Loef, Berthus Gerard IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it.

More information

Recognizing and Treating Patients with the Cardio-Renal Syndrome

Recognizing and Treating Patients with the Cardio-Renal Syndrome Recognizing and Treating Patients with the Cardio-Renal Syndrome Joachim H. Ix, MD, MAS, FASN Professor of Medicine Chief; Division of Nephrology-Hypertension University of California San Diego 1 Conflicts

More information

NOTES: CH 44 Regulating the Internal Environment (Homeostasis & The Urinary System)

NOTES: CH 44 Regulating the Internal Environment (Homeostasis & The Urinary System) NOTES: CH 44 Regulating the Internal Environment (Homeostasis & The Urinary System) HOMEOSTASIS **Recall HOMEOSTASIS is the steady-state physiological condition of the body. It includes: 1) Thermoregulation:

More information

Body Water Content Infants have low body fat, low bone mass, and are 73% or more water Total water content declines throughout life Healthy males are

Body Water Content Infants have low body fat, low bone mass, and are 73% or more water Total water content declines throughout life Healthy males are Fluid, Electrolyte, and Acid-Base Balance Body Water Content Infants have low body fat, low bone mass, and are 73% or more water Total water content declines throughout life Healthy males are about 60%

More information

The Excretory System. Biology 20

The Excretory System. Biology 20 The Excretory System Biology 20 Introduction Follow along on page 376 What dangers exist if your body is unable to regulate the fluid balance of your tissues? What challenged would the body have to respond

More information

For more information about how to cite these materials visit

For more information about how to cite these materials visit Author(s): Michael Heung, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Noncommercial Share Alike 3.0 License: http://creativecommons.org/licenses/by-nc-sa/3.0/

More information

PRINCIPLES OF DIURETIC ACTIONS:

PRINCIPLES OF DIURETIC ACTIONS: DIURETIC: A drug that increases excretion of solutes Increased urine volume is secondary All clinically useful diuretics act by blocking Na + reabsorption Has the highest EC to IC ratio = always more sodium

More information

Counter-Current System Regulation of Renal Functions

Counter-Current System Regulation of Renal Functions Counter-Current System Regulation of Renal Functions Assoc. Prof. MUDr. Markéta Bébarová, Ph.D. Department of Physiology Faculty of Medicine, Masaryk University This presentation includes only the most

More information

Human Anatomy and Physiology - Problem Drill 23: The Urinary System, Fluid, Electrolyte and Acid-Base Balance

Human Anatomy and Physiology - Problem Drill 23: The Urinary System, Fluid, Electrolyte and Acid-Base Balance Human Anatomy and Physiology - Problem Drill 23: The Urinary System, Fluid, Electrolyte and Acid-Base Balance Question No. 1 of 10 Which of the following statements about the functions of the urinary system

More information

Akash Ghai MD, FACC February 27, No Disclosures

Akash Ghai MD, FACC February 27, No Disclosures Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%

More information

Urinary System and Excretion. Bio105 Lecture 20 Chapter 16

Urinary System and Excretion. Bio105 Lecture 20 Chapter 16 Urinary System and Excretion Bio105 Lecture 20 Chapter 16 1 Outline Urinary System I. Function II. Organs of the urinary system A. Kidneys 1. Function 2. Structure III. Disorders of the urinary system

More information

BCH 450 Biochemistry of Specialized Tissues

BCH 450 Biochemistry of Specialized Tissues BCH 450 Biochemistry of Specialized Tissues VII. Renal Structure, Function & Regulation Kidney Function 1. Regulate Extracellular fluid (ECF) (plasma and interstitial fluid) through formation of urine.

More information

Outline Urinary System

Outline Urinary System Urinary System and Excretion Bio105 Lecture Packet 20 Chapter 16 Outline Urinary System I. Function II. Organs of the urinary system A. Kidneys 1. Function 2. Structure B. Urine formation 1. Hormonal regulation

More information

Osmoregulation and Renal Function

Osmoregulation and Renal Function 1 Bio 236 Lab: Osmoregulation and Renal Function Fig. 1: Kidney Anatomy Fig. 2: Renal Nephron The kidneys are paired structures that lie within the posterior abdominal cavity close to the spine. Each kidney

More information

State of the Art: acute heart failure Is it just congestion?

State of the Art: acute heart failure Is it just congestion? ESC CONGRESS 2017 Barcelona, 26. 30. August 2017 State of the Art: acute heart failure Is it just congestion? S.B. Felix, FESC Klinik für Innere Medizin B Ernst-Moritz-Arndt-Universität Greifswald 1456

More information

Renal System and Excretion

Renal System and Excretion Renal System and Excretion Biology 105 Lecture 19 Chapter 16 Outline Renal System I. Functions II. Organs of the renal system III. Kidneys 1. Structure 2. Function IV. Nephron 1. Structure 2. Function

More information

Fal Fal P h y s i o l o g y 6 1 1, S a n F r a n c i s c o S t a t e U n i v e r s i t y

Fal Fal P h y s i o l o g y 6 1 1, S a n F r a n c i s c o S t a t e U n i v e r s i t y Fall 12 OSMOTIC REGULATION OF THE RENAL SYSTEM: Effects of fasting and ingestion of water, coke, or Gatorade on urine flow rate and specific gravity Dorette Franks The purpose of the physiology experiment

More information

Principles of Renal Physiology. 4th Edition

Principles of Renal Physiology. 4th Edition Principles of Renal Physiology 4th Edition Principles of Renal Physiology 4th Edition Chris Lote Professor of Experimental Nephrology, University of Birmingham, UK SPRINGER SCIENCE+BUSINESS MEDIA, B.V.

More information

Pearls in Acute Heart Failure Management

Pearls in Acute Heart Failure Management Pearls in Acute Heart Failure Management Best Practices Juan M. Aranda Jr., M.D. Professor of Medicine Medical Director of Heart Failure/ Transplant Program University of Florida College of Medicine Disclosures:

More information

Ultrafiltration in Decompensated Heart Failure. Description

Ultrafiltration in Decompensated Heart Failure. Description Subject: Ultrafiltration in Decompensated Heart Failure Page: 1 of 7 Last Review Status/Date: September 2016 Ultrafiltration in Decompensated Heart Failure Description Ultrafiltration is a technique being

More information

The ability of the kidneys to regulate extracellular fluid volume by altering sodium

The ability of the kidneys to regulate extracellular fluid volume by altering sodium REGULATION OF EXTRACELLULAR FLUID VOLUME BY INTEGRATED CONTROL OF SODIUM EXCRETION Joey P. Granger Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Mississippi

More information

1. a)label the parts indicated above and give one function for structures Y and Z

1. a)label the parts indicated above and give one function for structures Y and Z Excretory System 1 1. Excretory System a)label the parts indicated above and give one function for structures Y and Z W- renal cortex - X- renal medulla Y- renal pelvis collecting center of urine and then

More information

Hyperaldosteronism: Conn's Syndrome

Hyperaldosteronism: Conn's Syndrome RENAL AND ACID-BASE PHYSIOLOGY 177 Case 31 Hyperaldosteronism: Conn's Syndrome Seymour Simon is a 54-year-old college physics professor who maintains a healthy lifestyle. He exercises regularly, doesn't

More information

Heart Failure (HF) Treatment

Heart Failure (HF) Treatment Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and

More information

Urinary Physiology. Chapter 17 Outline. Kidney Function. Chapter 17

Urinary Physiology. Chapter 17 Outline. Kidney Function. Chapter 17 Urinary Physiology Chapter 17 Chapter 17 Outline Structure and Function of the Kidney Glomerular Filtration Reabsorption of Salt and Water Renal Plasma Clearance Renal Control of Electrolyte and Acid-Base

More information

A. Study Purpose and Rationale Background

A. Study Purpose and Rationale Background A. Study Purpose and Rationale Background Congestive heart failure (CHF) affects roughly 6 million people in the United States with incidence rates rising steadily. Of even more concern, however, is the

More information

Diuretic Use in Neonates

Diuretic Use in Neonates Neonatal Nursing Education Brief: Diuretic Use in the Neonate http://www.seattlechildrens.org/healthcareprofessionals/education/continuing-medical-nursing-education/neonatalnursing-education-briefs/ Diuretics

More information

LESSON ASSIGNMENT. Diuretic and Antidiuretic Agents. After you finish this lesson you should be able to:

LESSON ASSIGNMENT. Diuretic and Antidiuretic Agents. After you finish this lesson you should be able to: LESSON ASSIGNMENT SUBCOURSE MD0806 LESSON 8 Therapeutics III. Diuretic and Antidiuretic Agents. LESSON ASSIGNMENT Paragraphs 8-1--8-7. LESSON OBJECTIVES After you finish this lesson you should be able

More information

Furosemide: Properties, Alternatives, and the Medication Approval Process. Heather Brown EMS 209-Advanced Pharmacology Don Knox

Furosemide: Properties, Alternatives, and the Medication Approval Process. Heather Brown EMS 209-Advanced Pharmacology Don Knox Furosemide: Properties, Alternatives, and the Medication Approval Process Heather Brown EMS 209-Advanced Pharmacology Don Knox Pre-hospital treatment of critical patients is a key factor in determining

More information

A. Correct! Flushing acids from the system will assist in re-establishing the acid-base equilibrium in the blood.

A. Correct! Flushing acids from the system will assist in re-establishing the acid-base equilibrium in the blood. OAT Biology - Problem Drill 16: The Urinary System Question No. 1 of 10 1. Which of the following would solve a drop in blood ph? Question #01 (A) Decreased retention of acids. (B) Increased excretion

More information

Excretory Lecture Test Questions Set 1

Excretory Lecture Test Questions Set 1 Excretory Lecture Test Questions Set 1 1. The separation and ejection of metabolic wastes, usually in aqueous solution, is: a. reabsorption b. secretion c. filtration d. excretion e. endocrinology 2. Besides

More information

1. Urinary System, General

1. Urinary System, General S T U D Y G U I D E 16 1. Urinary System, General a. Label the figure by placing the numbers of the structures in the spaces by the correct labels. 7 Aorta 6 Kidney 8 Ureter 2 Inferior vena cava 4 Renal

More information

Potassium regulation. -Kidney is a major regulator for potassium Homeostasis.

Potassium regulation. -Kidney is a major regulator for potassium Homeostasis. Potassium regulation. -Kidney is a major regulator for potassium Homeostasis. Normal potassium intake, distribution, and output from the body. Effects of severe hyperkalemia Partial depolarization of cell

More information

Renal System Physiology

Renal System Physiology M58_MARI0000_00_SE_EX09.qxd 7/18/11 2:37 PM Page 399 E X E R C I S E 9 Renal System Physiology Advance Preparation/Comments 1. Prior to the lab, suggest to the students that they become familiar with the

More information

Running head: NEPHRON 1. The nephron the functional unit of the kidney. [Student Name] [Name of Institute] Author Note

Running head: NEPHRON 1. The nephron the functional unit of the kidney. [Student Name] [Name of Institute] Author Note Running head: NEPHRON 1 The nephron the functional unit of the kidney [Student Name] [Name of Institute] Author Note NEPHRON 2 The nephron the functional unit of the kidney The kidney is an important excretory

More information